Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.

Manalan K, Green N, Arnold A, Cooke GS, Dedicoat M, Lipman M, Loyse A, Harrison TS, Kon OM.

J Infect. 2019 Sep 21. pii: S0163-4453(19)30277-4. doi: 10.1016/j.jinf.2019.09.006. [Epub ahead of print]

PMID:
31550466
2.

Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low- and moderate-incidence populations.

Braganza Menezes D, Menezes B, Dedicoat M.

Cochrane Database Syst Rev. 2019 Aug 28;8:CD013077. doi: 10.1002/14651858.CD013077.pub2.

PMID:
31461540
3.

Tuberculosis control in the United States: strengths, weaknesses, opportunities, threats.

Dedicoat M.

Int J Tuberc Lung Dis. 2019 Jul 1;23(7):773. doi: 10.5588/ijtld.19.0307. No abstract available.

PMID:
31439107
4.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
5.

Health-related quality of life and prevalence of six chronic diseases in homeless and housed people: a cross-sectional study in London and Birmingham, England.

Lewer D, Aldridge RW, Menezes D, Sawyer C, Zaninotto P, Dedicoat M, Ahmed I, Luchenski S, Hayward A, Story A.

BMJ Open. 2019 Apr 24;9(4):e025192. doi: 10.1136/bmjopen-2018-025192.

6.

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection.

O'Shea MK, Tanner R, Müller J, Harris SA, Wright D, Stockdale L, Stylianou E, Satti I, Smith SG, Dunbar J, Fletcher TE, Dedicoat M, Cunningham AF, McShane H.

Sci Rep. 2018 Sep 27;8(1):14480. doi: 10.1038/s41598-018-32755-x.

7.

Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease.

Moran E, Baharani J, Dedicoat M, Robinson E, Smith G, Bhomra P, Thien OS, Ryan R.

J Infect. 2018 Oct;77(4):291-295. doi: 10.1016/j.jinf.2018.06.003. Epub 2018 Jun 19.

PMID:
29928915
8.

Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases.

Scriven JE, Scobie A, Verlander NQ, Houston A, Collyns T, Cajic V, Kon OM, Mitchell T, Rahama O, Robinson A, Withama S, Wilson P, Maxwell D, Agranoff D, Davies E, Llewelyn M, Soo SS, Sahota A, Cooper MA, Hunter M, Tomlins J, Tiberi S, Kendall S, Dedicoat M, Alexander E, Fenech T, Zambon M, Lamagni T, Smith EG, Chand M.

Clin Microbiol Infect. 2018 Nov;24(11):1164-1170. doi: 10.1016/j.cmi.2018.04.027. Epub 2018 May 25.

9.

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D.

Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. Erratum in: Lancet Respir Med. 2018 Apr 18;:.

PMID:
29595509
10.

Acceptability of latent tuberculosis testing of migrants in a college environment in England.

Walker CL, Duffield K, Kaur H, Dedicoat M, Gajraj R.

Public Health. 2018 May;158:55-60. doi: 10.1016/j.puhe.2018.02.004. Epub 2018 Mar 19.

PMID:
29567507
11.

Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; for TBNET.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):379-386. doi: 10.1164/rccm.201710-2141OC.

PMID:
29509468
12.

Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015.

Loutet MG, Davidson JA, Brown T, Dedicoat M, Thomas HL, Lalor MK.

Emerg Infect Dis. 2018 Mar;24(3):524-533. doi: 10.3201/eid2403.171362.

13.

Mycobacterium shimoidei: an uncommon non-tuberculous infection in a UK patient.

Braganza Menezes DA, Dedicoat MJ, Robertson A.

BMJ Case Rep. 2018 Feb 2;2018. pii: bcr-2017-221764. doi: 10.1136/bcr-2017-221764.

PMID:
29420243
14.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

15.

A retrospective cohort study of patients treated with anti-tuberculous therapy for presumed ocular tuberculosis.

Damato EM, Dawson S, Liu X, Mukherjee C, Horsburgh J, Denniston AK, Moran E, Dedicoat M, Murray PI.

J Ophthalmic Inflamm Infect. 2017 Dec 4;7(1):23. doi: 10.1186/s12348-017-0141-4.

16.

Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.

Arnold A, Cooke GS, Kon OM, Dedicoat M, Lipman M, Loyse A, Chis Ster I, Harrison TS.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e02586-16. doi: 10.1128/AAC.02586-16. Print 2017 Sep.

17.

Treatment outcomes of MDR-TB and HIV co-infection in Europe.

Magis-Escurra C, Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBnet.

Eur Respir J. 2017 Jun 8;49(6). pii: 1602363. doi: 10.1183/13993003.02363-2016. Print 2017 Jun. No abstract available.

18.

Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.

Dedicoat MJ, Günther G, Crudu V, Duarte R, Gualano G, Magis-Escurra C, Rumetshofer R, Skrahina A, Spinu V, Tiberi S, Viiklepp P, van Leth F, Lange C; for TBNET ‡.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1222-1224. doi: 10.1164/rccm.201612-2585LE. No abstract available.

PMID:
28323453
19.

Latent tuberculous screening of recent migrants attending language classes: a cohort study and cost analysis.

Usdin M, Dedicoat M, Gajraj R, Harrison P, Kaur H, Duffield K, Walker CL, Akram Y, Aiyedun V, Mohamed H, Zenner D.

Int J Tuberc Lung Dis. 2017 Feb 1;21(2):175-180. doi: 10.5588/ijtld.16.0398.

PMID:
28234081
20.

Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008-2014.

Arnold A, Cooke GS, Kon OM, Dedicoat M, Lipman M, Loyse A, Butcher PD, Ster IC, Harrison TS.

J Infect. 2017 Mar;74(3):260-271. doi: 10.1016/j.jinf.2016.12.005. Epub 2016 Dec 18.

21.

Programmatic utility of tuberculosis cluster investigation using a social network approach in Birmingham, United Kingdom.

Munang ML, Browne C, Evans JT, Smith EG, Hawkey PM, Welch SB, Kaur H, Dedicoat MJ.

Int J Tuberc Lung Dis. 2016 Oct;20(10):1300-1305.

PMID:
27725038
22.

Using bedaquiline and delamanid in combination and safely.

Dedicoat M.

Int J Tuberc Lung Dis. 2016 Oct;20(10):1282. No abstract available.

PMID:
27725032
23.

Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBNET.

N Engl J Med. 2016 Sep 15;375(11):1103-5. doi: 10.1056/NEJMc1603274. No abstract available.

24.

Can routine genetic testing help to end TB transmission?

Dedicoat M, Cooke GS.

Thorax. 2016 Aug;71(8):681-2. doi: 10.1136/thoraxjnl-2016-208554. No abstract available.

PMID:
27417279
25.

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.

Günther G, van Leth F, Altet N, Dedicoat M, Duarte R, Gualano G, Kunst H, Muylle I, Spinu V, Tiberi S, Viiklepp P, Lange C; TBNET.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1524-7. doi: 10.5588/ijtld.15.0274.

PMID:
26614196
26.

Testing for latent tuberculosis infection using interferon gamma release assays in commercial sex workers at an outreach clinic in Birmingham.

Daly R, Khatib N, Larkins A, Dedicoat M.

Int J STD AIDS. 2016 Jul;27(8):676-9. doi: 10.1177/0956462415619261. Epub 2015 Nov 20.

PMID:
26589629
27.

Vitamin D deficiency and TB disease phenotype.

Pareek M, Innes J, Sridhar S, Grass L, Connell D, Woltmann G, Wiselka M, Martineau AR, Kon OM, Dedicoat M, Lalvani A.

Thorax. 2015 Dec;70(12):1171-80. doi: 10.1136/thoraxjnl-2014-206617. Epub 2015 Sep 23.

28.

Tuberculosis preventive chemotherapy: the times they are a-changin'.

Dedicoat M, Lange C.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1002. doi: 10.5588/ijtld.15.0599. No abstract available.

PMID:
26260815
29.

Tuberculosis microepidemics among dispersed migrants, Birmingham, UK, 2004-2013.

Munang ML, Browne C, Khanom S, Evans JT, Smith EG, Hawkey PM, Kunst H, Welch SB, Dedicoat MJ.

Emerg Infect Dis. 2015 Mar;21(3):524-7. doi: 10.3201/eid2103.140209.

30.

Multidrug-resistant tuberculosis in Europe, 2010-2011.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Pontali E, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; TBNET.

Emerg Infect Dis. 2015 Mar;21(3):409-16. doi: 10.3201/eid2103.141343.

31.

Low dose versus high dose stavudine for treating people with HIV infection.

Magula N, Dedicoat M.

Cochrane Database Syst Rev. 2015 Jan 28;1:CD007497. doi: 10.1002/14651858.CD007497.pub2. Review.

PMID:
25627012
32.

Percutaneous breast implant herniation: a rare complication of miliary TB.

Dale AP, Dedicoat MJ, Saleem T, Moran E.

BMJ Case Rep. 2015 Jan 7;2015. pii: bcr2014207546. doi: 10.1136/bcr-2014-207546.

33.

Tuberculosis: a perennial pain in the posterior?

Yim GH, Bowley DM, Dedicoat MJ, Bailey MS.

Int J Colorectal Dis. 2015 Jun;30(6):849-50. doi: 10.1007/s00384-014-2049-x. Epub 2014 Nov 6. No abstract available.

PMID:
25374416
34.

Novel drugs and drug combinations for treating tuberculosis.

Munang ML, O'Shea MK, Dedicoat M.

BMJ. 2014 Oct 16;349:g5948. doi: 10.1136/bmj.g5948. No abstract available.

PMID:
25324128
35.

Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.

Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE.

Cochrane Database Syst Rev. 2014;(9):CD003256. Review.

PMID:
25313415
36.

Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.

Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE.

Cochrane Database Syst Rev. 2014 Aug 13;(8):CD003256. doi: 10.1002/14651858.CD003256.pub2. Review.

37.

Tuberculosis transmission.

Munang ML, Dedicoat M.

J Am Dent Assoc. 2014 Aug;145(8):800-1. No abstract available.

PMID:
25082928
38.

Isoniazid-resistant tuberculosis in Birmingham, United Kingdom, 1999-2010.

Munang ML, Kariuki M, Dedicoat M.

QJM. 2015 Jan;108(1):19-25. doi: 10.1093/qjmed/hcu139. Epub 2014 Jul 1.

PMID:
24989780
39.

Predictors of contact tracing completion and outcomes in tuberculosis: a 21-year retrospective cohort study.

Saunders MJ, Koh GC, Small AD, Dedicoat M.

Int J Tuberc Lung Dis. 2014 Jun;18(6):640-6. doi: 10.5588/ijtld.13.0486.

PMID:
24903932
40.

Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.

O'Shea MK, Fletcher TE, Beeching NJ, Dedicoat M, Spence D, McShane H, Cunningham AF, Wilson D.

PLoS One. 2014 May 9;9(5):e97366. doi: 10.1371/journal.pone.0097366. eCollection 2014.

41.

Time-to-detection in culture predicts risk of Mycobacterium tuberculosis transmission: a cohort study.

O'Shea MK, Koh GC, Munang M, Smith G, Banerjee A, Dedicoat M.

Clin Infect Dis. 2014 Jul 15;59(2):177-85. doi: 10.1093/cid/ciu244. Epub 2014 Apr 11.

PMID:
24729491
42.

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET.

Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.

43.

Tuberculosis control in big cities and urban risk groups in the European Union: a consensus statement.

van Hest NA, Aldridge RW, de Vries G, Sandgren A, Hauer B, Hayward A, Arrazola de Oñate W, Haas W, Codecasa LR, Caylà JA, Story A, Antoine D, Gori A, Quabeck L, Jonsson J, Wanlin M, Orcau Å, Rodes A, Dedicoat M, Antoun F, van Deutekom H, Keizer S, Abubakar I.

Euro Surveill. 2014 Mar 6;19(9). pii: 20728.

44.

Culture confirmation of tuberculosis cases in Birmingham, UK.

Hayer KS, Sitch AJ, Dedicoat M, Wood AL.

Scand J Infect Dis. 2013 Oct;45(10):746-51. doi: 10.3109/00365548.2013.804944. Epub 2013 Aug 19.

PMID:
23957536
45.

Tuberculosis incidence correlates with sunshine: an ecological 28-year time series study.

Koh GC, Hawthorne G, Turner AM, Kunst H, Dedicoat M.

PLoS One. 2013;8(3):e57752. doi: 10.1371/journal.pone.0057752. Epub 2013 Mar 6.

46.

Mammary tuberculosis in the young: a case report and literature review.

Green M, Millar E, Merai H, O'Shea M, Dedicoat M, Ingle H.

Breast Dis. 2012;34(1):39-42. doi: 10.3233/BD-130343. Review.

PMID:
23443072
47.

Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study.

Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, Eyre DW, Wilson DJ, Hawkey PM, Crook DW, Parkhill J, Harris D, Walker AS, Bowden R, Monk P, Smith EG, Peto TE.

Lancet Infect Dis. 2013 Feb;13(2):137-46. doi: 10.1016/S1473-3099(12)70277-3. Epub 2012 Nov 15.

48.

Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype.

Pareek M, Evans J, Innes J, Smith G, Hingley-Wilson S, Lougheed KE, Sridhar S, Dedicoat M, Hawkey P, Lalvani A.

Thorax. 2013 Mar;68(3):221-9. doi: 10.1136/thoraxjnl-2012-201824. Epub 2012 Sep 27.

49.

The development and validation of a risk score for household infestation by Triatoma infestans, a Bolivian vector of Chagas disease.

Saunders M, Small A, Dedicoat M, Roberts L.

Trans R Soc Trop Med Hyg. 2012 Nov;106(11):677-82. doi: 10.1016/j.trstmh.2012.07.006. Epub 2012 Sep 10.

PMID:
22975298
50.

Rifampicin reduces methadone concentrations.

Dedicoat MJ.

BMJ. 2012 Jun 19;344:e4199. doi: 10.1136/bmj.e4199. No abstract available.

PMID:
22718900

Supplemental Content

Loading ...
Support Center